Editor’s Choice – Evaluating the Efficacy of Intra-articular Injections of Platelet Rich Plasma (PRP) in Rheumatoid Arthritis Patients and its Impact on Inflammatory Cytokines, Disease Activity and Quality of Life

Author(s):Dalia S. Saif*Nagwa N. Hegazy and Enas S. Zahran

Volume 17, Issue 2, 2021

Published on: 13 November, 2020

Page: [232 – 241]

Pages: 10

DOI: 10.2174/1573397116666201113090629

Abstract

Background: Among rheumatoid arthritis patients (RA), general disease activity is well regulated by disease-modifying anti-rheumatic medications (DMARDS), but sometimes local inflammation still persists among a few joints. Adjuvant modern molecular interventions as Platelet Rich Plasma (PRP) with a suggested down regulating effect on inflammatory mediators has a proven effect in the management of RA.We aim to evaluate the therapeutic effect of intra-articular PRP versus steroid in RA patients and their impact on inflammatory cytokines IL1B, TNF α, local joint inflammation, disease activity and quality of life (QL).

Methods: Open-labeled parallel randomized control clinical trial was carried out on 60 RA patients randomly divided into 2 groups, Group 1: included 30 patients received 3 intra-articular injections of PRP at a monthly interval, Group 2: included 30 patients received single intra-articular injection of steroid. They were subjected to clinical, laboratory, serum IL1B and TNF α assessment at baseline and at 3, and 6 months post injection.

Results: Patients of both groups showed improvements in their scores of evaluating tools at 3months post injection and this improvement was persistent in the PRP group up to 6 months post injection while it was continued only for 3 months in the steroid group.

Conclusion: PRP is a safe, effective and useful therapy in treating RA patients who had an insufficient response and persistent pain and inflammation in just one or two joints through its down regulating effect on inflammatory cytokines IL1B, TNF α with subsequent improvement of local joint inflammation, disease activity and QL. Read now: https://bit.ly/3UqgDVQ

Recent Issues of the Journals have been Published:

Cardiovascular & Hematological Disorders-Drug Targets, 14 Issue 2

Aims & Scope

Cardiovascular & Hematological Disorders-Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth, reviews, original research articles, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

 http://www.eurekaselect.com/123834/issue/2

Abstracted & Indexed in:

MEDLINE/Index Medicus, Scopus, CSA, BIOSIS Reviews Reports and Meetings, BIOSIS Previews, BIOSIS, BIOBASE, EMBASE/Excerpta Medica, MediaFinder®-Standard Periodical Directory, Genamics JournalSeek, PubsHub, J-Gate, Chemical Abstracts (CAS).

For more details, visit: http://benthamscience.com/journal/index.php?journalID=chddt

Letters in Drug Design & Discovery, 11 Issue 8

Aims & Scope

Letters in Drug Design & Discovery publishes letters, mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery. 

http://www.eurekaselect.com/123819/issue/8

Abstracted & Indexed in:

Journal Citation Reports/Science Edition, Science Citation Index ExpandedTM, Web of Science, ISI Alerting Service, Chemistry Citation Index®, Current Contents®/Physical, Chemical Abstracts, Chemical and Earth Sciences, Scopus, EMBASE, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub, J-Gate.

For more details, visit: http://benthamscience.com/journal/index.php?journalID=lddd

Current HIV Research, 12 Issue 3

 Aims & Scope

Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.

http://www.eurekaselect.com/123634/issue/3

Abstracted & Indexed in:

Science Citation Index Expanded™, Thomson Web of Science, ISI Alerting Services, Journal Citation Reports/Science Edition, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Chemical Abstracts, MEDLINE/Index Medicus, Scopus, EMBASE, EMBASE/Excerpta Medica, PubsHub, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, J-Gate, PubMed.

For more details, visit: http://benthamscience.com/journal/index.php?journalID=chivr

Current Organic Synthesis, 11 Issue 4

 Aims & Scope

Current Organic Synthesis publishes in-depth reviews, original research articles and letter/short communications on all areas of synthetic organic chemistry i.e. asymmetric synthesis, organometallic chemistry, novel synthetic approaches to complex organic molecules, carbohydrates, polymers, protein chemistry, DNA chemistry, supramolecular chemistry, molecular recognition and new synthetic methods in organic chemistry. The frontier reviews provide the current state of knowledge in these fields and are written by experts who are internationally known for their eminent research contributions. The journal is essential reading to all synthetic organic chemists. Current Organic Synthesis should prove to be of great interest to synthetic chemists in academia and industry who wish to keep abreast with recent developments in key fields of organic synthesis.

http://www.eurekaselect.com/123610/issue/4

Abstracted & Indexed in:

Science Citation Index Expanded (SciSearch®), ISI Alerting Services, Chemistry Citation Index®, BIOSIS Review Report and Meetings, Current Contents® / Physical, Chemical and Earth Sciences, BIOSIS Previews, Journal Citation Reports/Science Edition, Scopus, Genamics JournalSeek, Chemical Abstracts, PubsHub, J-Gate, MediaFinder®-Standard Periodical Directory.

For more details, visit: http://benthamscience.com/journal/index.php?journalID=cos

Current Pharmaceutical Biotechnology, 15 Issue 2

 Aims & Scope

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews, research articles and letters written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

Current Pharmaceutical Biotechnology is excelling in impact to be the number one journal in its field.

http://www.eurekaselect.com/123825/issue/2

Abstracted & Indexed in:

Chemical Abstracts, MEDLINE/Index Medicus, BIOSIS, EMBASE/Excerpta Medica, BIOBASE, Science Citation Index Expanded, Biochemistry & Biophysics Citation Index, Journal Citation Reports/Science Edition, Current Contents®/Life Sciences, Biotechnology Citation IndexTM, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Index to Scientific Reviews®, Scopus, EMBiology, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub, J-Gate.

For more details, visit: http://benthamscience.com/journal/index.php?journalID=cpb

%d bloggers like this: